semaglutide fda shortage status january 2025 semaglutide injection product shortage is resolved - Tirzepatideshortage semaglutide shortage on Feb 21, 2025 Semaglutide FDA Shortage Status: January 2025 Update and Resolution

Semaglutide shortagelist The pharmaceutical landscape has seen significant shifts regarding the availability of semaglutide, a crucial medication in the management of type 2 diabetes and chronic weight managementAs of February 21, 2025, the FDA updated its drug .... For an extended period, the FDA has grappled with a national shortage of semaglutide injection products, impacting patients reliant on popular brand names like Ozempic and Wegovy.Semaglutide's removal from the FDA shortages list sets ... However, as of January 2025, and definitively by February 21, 2025, the FDA has declared the semaglutide injection product shortage is resolved. This resolution marks a significant milestone, affecting market dynamics, compounding pharmacy practices, and patient access.

Understanding the Semaglutide Shortage and its Resolution

The semaglutide shortage became a prominent concern starting in early 20222025年2月21日—The US Food and Drug Administration (FDA) has declared the shortage ofsemaglutide injection (Ozempic) and semaglutide injection 2.4 mg (Wegovy) is over.. This scarcity led to widespread discussions and reports concerning semaglutide shortage update and its potential end. The FDA has been meticulously monitoring the situation, with its latest assessments confirming that the supply of semaglutide injection products now meets or exceeds both current and projected demands in the United States. This declaration signifies that the semaglutide injection shortage observed in early 2025 has officially concluded.2025年3月21日—TheFDAissued guidance clarifying that 503A and 503B drug compounders must soon cease compoundingsemaglutideinjection products.

On February 21, 2025, the FDA updated its drug shortage list, officially labeling the semaglutide injection shortage as resolved. This decision was based on comprehensive analysis, indicating a substantial improvement in the availability of semaglutide doses, including those for Ozempic and Wegovy. The FDA has confirmed that the shortage of all doses of injectable semaglutide at the manufacturer level has ended. Notably, some sources indicate the semaglutide shortage was resolved on February 21, 2025, with earlier indications suggesting the semaglutide will be off the shortage list before 2026FDA clarifies policies for compounders as national GLP-1 ....

Key Dates and Declarations

The official end of the semaglutide shortage hinges on several key dates and FDA declarations:

* February 21, 2025: This is the pivotal date when the FDA officially determined that the semaglutide injection products are no longer in a state of shortage2025年2月21日—TheFDAhas officially declared an end to the supply squeeze on Novo Nordisk's diabetes and obesity counterpartsemaglutidein the US.. This declaration was reiterated on multiple occasions, confirming that the semaglutide shortage is officially over.

* Post-Shortage Clarifications: Following the resolution of the semaglutide shortage, the FDA issued guidance clarifying policies for compounders.As of February 21, 2025, the FDA updated its drug shortage list, marking thesemaglutide injection shortage as resolved. This included a cease-and-desist notice for compounding semaglutide injection products, particularly for those intended for mass marketing.FDA Resolves Semaglutide Shortage: Next Steps ...

Implications of the Resolved Shortage

The resolution of the semaglutide shortage carries significant implications:

For Patients and Prescribers

Patients who have been experiencing difficulties accessing their prescribed semaglutide medications, such as Ozempic and Wegovy, can now expect improved availability.2025年8月19日—The FDA endedthe semaglutide shortage on Feb 21, 2025. Learn key deadlines for compounded semaglutide, GLP-1 alternatives and more. This also impacts the choice between branded and compounded semaglutide. While compounded semaglutide emerged as an alternative during the shortage, the FDA's stance has shifted post-resolution.

For Compounding Pharmacies

The FDA’s decision on February 21, 2025, that the semaglutide shortage was resolved effectively means that compounding pharmacies must cease compounding semaglutide injection products[2/21/2025]FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection .... The FDA has issued guidance clarifying that 503A and 503B drug compounders must soon stop this practice.When did the semaglutide shortage end? The FDA ruled thatsemaglutide was no longer in shortage on February 21, 2024. That decision was ... This directly impacts the availability of compounded semaglutide and raises questions about its future. The FDA has also clarified its policies for compounders as the national GLP-1 medication situation evolves.

Market Dynamics and Alternatives

The end of the semaglutide shortage also influences the broader market for GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. While semaglutide is now more readily available, the high demand for these medications persists. This has spurred interest in semaglutide alternatives and ongoing research into new formulations, such as oral semaglutide options.2025年2月27日—TheFDAannounced that theshortageofsemaglutide(Wegovy, Ozempic; Novo Nordisk) is resolved and now meets or exceeds both current and projected US demands. The FDA's actions also highlight the importance of regulatory oversight in ensuring drug availability and safety.2025年3月6日—On February 21,2025, the US Food and Drug Administration (FDA) revised itsshortagecategorization ofsemaglutide, a glucagon-like peptide 1 (GLP-1) ...

Looking Ahead: January 2025 and Beyond

As of January 2025, the anticipation surrounding the resolution of the semaglutide shortage was high, with many sources predicting its imminent end. By February 21, 2025, this prediction became a reality. The FDA's confirmation that semaglutide injection products are no longer on the shortage list signifies a return to more normalized supply chains for these critical medicationsBest Semaglutide Options for 2026: New Oral Wegovy Pill Approved by ....

While the semaglutide shortage has officially concluded, the high demand for semaglutide and related medications continues.2025年2月22日—FDA says thesemaglutide shortage is officially over. Is this the end of the line compounding pharmacies, or the start of a new chapter? This sustained interest underscores the transformative impact of semaglutide on treating conditions like type 2 diabetes and obesity. The FDA’s proactive stance and clear communication throughout this period have been crucial in navigating the complexities of drug supply and ensuring patient access to essential treatments.2025年2月21日—FDA has determined that thesemaglutide injection product shortage is resolved. This determination is based on the analysis set forth in FDA's ... The successful resolution of the semaglutide shortage in 2025 is a testament to the collaboration between regulatory bodies, pharmaceutical manufacturers, and healthcare providers.